The diagnostic radiopharmaceuticals and contrast media market is expected to register a CAGR of 5.29% over the forecast period.
The COVID-19 pandemic is expected to have impacted the growth of the studied market. According to the research study published in the Journal of Nuclear Medicine, July 2020, many countries were experiencing radiopharmaceutical supply issues, with lower-income regions suffering the worst. Furthermore, according to a survey conducted in the study “Nuclear medicine volume plummets due to COVID-19” published in September 2020, the scheduled diagnostic and therapeutic nuclear imaging procedures were quantitatively reduced by 50% to 75% respectively in the United States during the pandemic. Thus, owing to the aforementioned factors, the studied market is expected to witness a short-term negative impact during the pandemic.
The diagnostic radiopharmaceuticals and contrast media market is expected to grow over the forecast period due to factors such as technological developments, increasing diagnostic applications in various diseases, growing government support, and rising cases of chronic diseases such as cancers and cardiovascular diseases globally. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers, globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Hence, the growing burden of cancers is expected to drive the demand for diagnostics and effective treatment, which in turn drives the growth of the studied market. Furthermore, the development of minimally invasive therapeutic procedures has encouraged the usage of imaging equipment. This increase in the demand for image guidance is expected to propel the market. Also, Government initiatives and funding for the development of new techniques are anticipated to drive the growth of the studied market. For instance, in July 2019, a new bill named Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 passed by the government of United States. The new bill aims to extend access to high-targeted, and more precise diagnosis and treatment of severe neurological diseases, by changing the way of medicare payments for imaging services. However, the factors such as a shorter half-life of radiopharmaceuticals, stringent regulatory framework, and high capital investment, are expected to hinder the market growth.
Key Market Trends
Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance Over the Forecast Period
The growing burden of cardiovascular diseases is expected to drive the growth of the studied segment. The incidence of cardiovascular diseases has increased over the years and is expected to increase in the future as well, as per a 2019 study by the American Heart Association. As per the 2020 updates of the World Health Organization, ischemic heart disease is responsible for 16% of the world’s total deaths. Since 2000, the largest increase in deaths has been for ischemic heart disease, rising by more than 2 million to 8.9 million deaths in 2019 globally. Furthermore, according to the British Heart Foundation Centre in 2018, there were around 7.4 million people living with heart and circulatory diseases in the United Kingdom. More than 43,000 people under the age of 75 in the United Kingdom die from heart and circulatory diseases each year. SPECT, which stands for single-photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the studied segment over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance Over the Forecast Period
North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. In the North American region, the burden of Cardiac disorder is also high. According to the American Heart Association Research Report 2018, coronary heart disease was the leading cause (43.8%) of deaths attributable to cardiovascular disease in the United States, followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), diseases of the arteries (3.1%), and other cardiovascular diseases (17.9%). According to the Global Health and Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition. As radiopharmaceuticals and contrast imaging show huge potential in the diagnosis of cardiac, the studied market is likely to propel in the North American region. Additionally, in 2020, the Department of Energy’s National Nuclear Security Administration (NNSA) awarded a three-year, USD 750,000 grant to the Radiological Society of North America. This will help expand access to this vital knowledge to a part of the world that needs these nuclear imaging services. Furthermore, the increase in product approvals is expected to drive market growth. For instance, in September 2019, Curium Pharma and PadioMedix Inc. received United States Food and Drug Administration approval for its Detectnet (copper Cu 64 dotatate injection), which is a positron emission tomography (PET) agent for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients. Hence, owing to the aforementioned factors, the North American diagnostic radiopharmaceuticals, and contrast media market is expected to retain its dominance over the forecast period.
The Diagnostic radiopharmaceuticals and Contrast Media Market is moderately competitive and consists of few major players dominating the global market. The presence of major market players, such as Bayer AG, GE Company (GE Healthcare), Cardinal Health Inc., Siemens Healthineers, Bracco Imaging SpA., Curium Pharma, and Guerbet Group, is, in turn, increasing the overall competitive rivalry of the market. The major players are evolving through strategic alliances such as acquisitions, mergers, partnerships, and collaborations, along with new product launches and investment in research and development activities to secure the position in a globally competitive market. For instance, in March 2020, Curium Pharma completed the acquisition of Zevacor Molecular, which is involved in the production of Strontium-82, which is used in the production of Rubidium-82 generators for cardiac PET imaging in the United States
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Technology Advancements in Medical Imaging
4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
4.2.3 High Prevalence of Cancers and Cardiac Diseases
4.3 Market Restraints
4.3.1 High Costs of the Techniques
4.3.2 Limited Health Insurance Coverage
4.3.3 Short Half-life of Radiopharmaceuticals
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 By Type of Imaging Modality
184.108.40.206.5 Other SPECTs
220.127.116.11.3 Other PETs
5.1.2 By Application
18.104.22.168 Diagnostic Application
22.214.171.124.1 SPECT Applications
126.96.36.199.1.4 Other SPECT Applications
188.8.131.52.2 PET Application
184.108.40.206.2.4 Other PET Applications
220.127.116.11 Therapeutic Application
18.104.22.168.3 Endocrine Tumors
22.214.171.124.4 Other Therapeutic Applications
5.2 Contrast Media
5.2.1 By Type
126.96.36.199 Iodinated Contrast Media
188.8.131.52 Gadolinium-based Contrast Media
184.108.40.206 Microbubble Contrast Media
220.127.116.11 Barium-based Contrast Media
5.2.2 By Procedure
18.104.22.168 X-ray/Computed Tomography (CT)
22.214.171.124 Magnetic Resonance Imaging (MRI)
5.2.3 By Application
126.96.36.199 Cardiovascular Disease
188.8.131.52 Gastrointestinal Disorders
184.108.40.206 Neurological Disorders
220.127.116.11 Other Indications
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6.1.1 NTP Radioisotopes SOC Ltd
6.1.2 Bayer AG
6.1.3 Bracco Imaging SpA
6.1.4 Curium Pharma
6.1.5 GE Company (GE Healthcare)
6.1.6 Guerbet Group
6.1.7 Lantheus Holdings Inc.
6.1.8 Cardinal Health Inc.
6.1.9 Nano Therapeutics Pvt. Ltd.
6.1.10 Siemens Healthineers
6.1.11 Trivitron Healthcare
6.1.12 Koninklijke Philips N.V.
6.1.13 Triad Isotopes
6.1.14 Spago Nanomedical AB
6.1.15 Otsuka Pharmaceuticals Co. Ltd.
A selection of companies mentioned in this report includes:
- NTP Radioisotopes SOC Ltd
- Bayer AG
- Bracco Imaging SpA
- Curium Pharma
- GE Company (GE Healthcare)
- Guerbet Group
- Lantheus Holdings Inc.
- Cardinal Health Inc.
- Nano Therapeutics Pvt. Ltd.
- Siemens Healthineers
- Trivitron Healthcare
- Koninklijke Philips N.V.
- Triad Isotopes
- Spago Nanomedical AB
- Otsuka Pharmaceuticals Co. Ltd.